GB Sciences OTCPK:GBLX Stock Report GB Sciences, Inc.
OTCPK:GBLX Stock Report
GBLX Stock Overview A plant-based research and biopharmaceutical drug development company.
Rewards Risk Analysis + 2 more risks
See All Risk Checks GB Sciences, Inc. Competitors Price History & Performance
Summary of all time highs, changes and price drops for GB Sciences Historical stock prices Current Share Price US$0.0002 52 Week High US$0.013 52 Week Low US$0.000001 Beta 0.60 11 Month Change -97.44% 3 Month Change -97.14% 1 Year Change -97.14% 33 Year Change -99.35% 5 Year Change -99.65% Change since IPO -99.99%
Recent News & Updates GB Sciences, Inc. announced delayed 10-Q filing Aug 15
GB Sciences, Inc. announced delayed annual 10-K filing Jul 02
GB Sciences, Inc. announced delayed 10-Q filing Nov 15
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge Jul 12
GB Sciences, Inc. announced delayed annual 10-K filing Jul 01
GB Sciences, Inc., Annual General Meeting, Mar 09, 2023 Jan 20 See more updates GB Sciences, Inc. announced delayed 10-Q filing Aug 15
GB Sciences, Inc. announced delayed annual 10-K filing Jul 02
GB Sciences, Inc. announced delayed 10-Q filing Nov 15
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge Jul 12
GB Sciences, Inc. announced delayed annual 10-K filing Jul 01
GB Sciences, Inc., Annual General Meeting, Mar 09, 2023 Jan 20
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada Oct 25
GB Sciences, Inc. announced delayed annual 10-K filing Jul 01
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article Mar 30
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis Mar 03
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million. Jan 13
GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation Sep 15
GB Sciences, Inc. announced delayed annual 10-K filing Jul 02
GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of Directors Nov 26
Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX). Sep 19
GB Sciences, Inc. announced delayed 10-Q filing Aug 18
GB Sciences, Inc. announced delayed annual 10-K filing Aug 14 Shareholder Returns GBLX US Pharmaceuticals US Market 7D 0% 1.1% 5.7% 1Y -97.1% 16.6% 36.9%
See full shareholder returns
Return vs Market: GBLX underperformed the US Market which returned 36.3% over the past year.
Price Volatility Is GBLX's price volatile compared to industry and market? GBLX volatility GBLX Average Weekly Movement 3,947.2% Pharmaceuticals Industry Average Movement 9.4% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: GBLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GBLX's weekly volatility has increased from 1992% to 3947% over the past year.
About the Company GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs.
Show more GB Sciences, Inc. Fundamentals Summary How do GB Sciences's earnings and revenue compare to its market cap? GBLX fundamental statistics Market cap US$122.12k Earnings (TTM ) -US$1.64m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GBLX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$1.64m Earnings -US$1.64m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -0.004 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -33.1%
How did GBLX perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
